For pharmaceutical companies, aligning equitable access with commercial sustainability is one of the toughest challenges in healthcare today, especially through equity pricing. Too often, pricing approaches emerge reactively, shaped by short-term opportunities instead of a unified strategy. The challenge also stems from a fragmented dialogue that includes NGOs, governments, and industry voices. What is missing is a clear, pharma-specific framework to guide decisions.
Equity Pricing: Strategies for Pharmaceutical Companies
Our new White Paper addresses this critical issue directly.
Inside, we explore:
- The vision for equitable access
- Pricing principles and tools companies can use
- Tactical pillars to apply in a measurable and sustainable way
The White Paper differentiates three principles that often guide price setting: value, cost, or ability to pay. Particular attention is given to equity pricing, which lacks formal processes such as HTA, clear assessment criteria, or established formulas like cost-plus markups. Because of this, it remains both conceptually ambiguous and operationally difficult to apply. The choice of principle depends on several factors, including product type, market segment, and disease context.
Equity Pricing: Real-World Examples
The White Paper present cases where companies applied tailored pricing for high-value treatments. Examples include neuroscience, rare diseases, and cancer.
While these cases are useful, little public information explains how organisations moved from vision to implementation.
This gap presents a real opportunity for leaders. Sharing not only what was done, but also why, how, and with what impact, could shape the future of access.
Equity Pricing: The Journey from Ambiguity to Action
Ultimately, the journey from ambiguity to action is dynamic and ongoing. As more companies adopt structured approaches, the focus will shift toward outcomes, evidence, and shared insight. By fostering transparency, collaboration, and innovation, the industry can further drive a future of equitable access to medicines.